% 0期刊文章%杰西雅各布森%又是一个哈立德Ghoniem %艾丹马伦% Turcano % Emanuele Camerucci %一个科尔刺伤% Rodolfo Savica詹姆斯·鲍尔% % T冲动控制障碍和药物管理患者的早发性帕金森病(p6 - 11.013) % D R 10.1212 / WNL 2023%。0000000000203838 % J首页神经病学% P V 100% N 17补充2% 4230% X目的:评估多巴胺受体激动剂的使用频率(DA),冲动控制障碍的患病率(ICD)患者的早发性帕金森病(EOPD),并探讨与ICD的发展相关联的潜在因素。背景:冲动控制障碍的特点是过度和重复性行为通常影响患者暴露于哒。在先前的研究中,据报道,1)的患病率增加ICD患者的帕金森症和2)ICD发生与雄性和早期疾病发病相关。EOPD早期疾病发作,患者经常面临独特的临床和社会挑战。考虑到这些因素和当前的文学在EOPD ICD,重要的是要提高我们理解ICD的脆弱人群。设计/方法:我们使用了梅奥数据浏览系统调查以人群为基础的队列EOPD梅约诊所的病人在1990年到2022年之间。我们包括帕金森氏症患者在50岁或之前(根据当前社会运动障碍的建议)诊断为ICD。综述了所有病历证实诊断。结果:共有838名患者(518男性和320女性)EOPD包括症状出现的平均年龄为40.6±6.7年。DA在47.4%的病人。24.2%的患者使用DA ICD,在这些患者中,26%女性和23.1%男性ICD。 There was no statistically significant difference in the frequency of ICD between males and females (p = 0.59).Conclusions: Our study demonstrates that DA was frequently used in patients with EOPD and that about 25% of these patients are affected by ICD. Our study also showed that there was no significant difference in the prevalence of ICD development between female and male patients.Disclosure: Dr. Jacobson has nothing to disclose. Dr. Ghoniem has nothing to disclose. Aidan Mullan has nothing to disclose. Dr. Turcano has nothing to disclose. Dr. Camerucci has nothing to disclose. Mr. Stang has nothing to disclose. The institution of Dr. Bower has received research support from Abbvie. The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc. %U

map